DE68913756T2 - In vivo cytoprotektiv wirkende neurotrope alkohole. - Google Patents

In vivo cytoprotektiv wirkende neurotrope alkohole.

Info

Publication number
DE68913756T2
DE68913756T2 DE68913756T DE68913756T DE68913756T2 DE 68913756 T2 DE68913756 T2 DE 68913756T2 DE 68913756 T DE68913756 T DE 68913756T DE 68913756 T DE68913756 T DE 68913756T DE 68913756 T2 DE68913756 T2 DE 68913756T2
Authority
DE
Germany
Prior art keywords
neurotrope
alcohols
cytoprotective
vivo
vivo cytoprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68913756T
Other languages
English (en)
Other versions
DE68913756D1 (de
Inventor
Jacques Borg
Carl Cotman
J Kesslak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE68913756D1 publication Critical patent/DE68913756D1/de
Application granted granted Critical
Publication of DE68913756T2 publication Critical patent/DE68913756T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE68913756T 1988-10-18 1989-10-16 In vivo cytoprotektiv wirkende neurotrope alkohole. Expired - Fee Related DE68913756T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25991888A 1988-10-18 1988-10-18
US25992888A 1988-10-18 1988-10-18
US25991988A 1988-10-18 1988-10-18
US25996488A 1988-10-18 1988-10-18
US26930088A 1988-11-09 1988-11-09
PCT/US1989/004630 WO1990004388A1 (en) 1988-10-18 1989-10-16 In vivo neurotrophic cytoprotective alcohols

Publications (2)

Publication Number Publication Date
DE68913756D1 DE68913756D1 (de) 1994-04-14
DE68913756T2 true DE68913756T2 (de) 1994-08-11

Family

ID=27540413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68913756T Expired - Fee Related DE68913756T2 (de) 1988-10-18 1989-10-16 In vivo cytoprotektiv wirkende neurotrope alkohole.

Country Status (8)

Country Link
US (1) US5135956A (de)
EP (1) EP0439544B1 (de)
JP (1) JPH04505003A (de)
AU (1) AU633526B2 (de)
CA (1) CA2000940A1 (de)
DE (1) DE68913756T2 (de)
DK (1) DK69091A (de)
WO (1) WO1990004388A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5070107A (en) * 1989-04-28 1991-12-03 Lidak Pharmaceuticals Systemic antiviral treatment
US5071879A (en) * 1989-04-28 1991-12-10 Lidak Pharmaceuticals Systemic antiviral treatment
EP0448697B1 (de) * 1989-10-13 1996-04-10 Neurofit Analoge von vitamin a und ihre verwendung, insbesondere als cytotrophische und cytoprotective substanzen sowie diese substanzen enthaltende arzneimittel
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
US6174862B1 (en) * 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
AU6836394A (en) * 1993-06-01 1994-12-20 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
US5952392A (en) * 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
US6962930B1 (en) 1997-06-06 2005-11-08 Lohocla Research Corporation Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6265147B1 (en) 1999-12-01 2001-07-24 The Board Of Trustees Of The Leland Stanford Junior University Method of screening for neuroprotective agents
CA2421026C (en) * 2001-10-16 2005-02-15 Avanir Pharmaceuticals Viral inhibition by n-docosanol
US7214394B2 (en) * 2002-05-31 2007-05-08 Archer-Daniels-Midland Company Policosanol compositions, extraction from novel sources, and uses thereof
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
US8202541B2 (en) * 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
ES2388827T3 (es) * 2008-04-03 2012-10-19 F. Hoffmann-La Roche Ag Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares
WO2013082299A1 (en) 2011-11-29 2013-06-06 Als Therapy Development Institute Targeting of t-lymphocytes to treat amyotrophic lateral sclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031376A (en) * 1956-10-11 1962-04-24 Levin Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same
US4186212A (en) * 1978-03-09 1980-01-29 Howell F Maurice Animal feed containing high molecular weight aliphatic alcohols
US5055613A (en) * 1988-02-18 1991-10-08 G. D. Searle & Co. Metabolites of pentanedioic acid derivatives
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment

Also Published As

Publication number Publication date
DK69091D0 (da) 1991-04-17
EP0439544B1 (de) 1994-03-09
AU633526B2 (en) 1993-02-04
US5135956A (en) 1992-08-04
AU4510889A (en) 1990-05-14
DE68913756D1 (de) 1994-04-14
CA2000940A1 (en) 1990-04-18
DK69091A (da) 1991-06-14
EP0439544A1 (de) 1991-08-07
WO1990004388A1 (en) 1990-05-03
JPH04505003A (ja) 1992-09-03

Similar Documents

Publication Publication Date Title
DE68913756T2 (de) In vivo cytoprotektiv wirkende neurotrope alkohole.
DE58906349D1 (de) Endoskop.
FI894095A0 (fi) Vaermare foer anvaendning i mikrovaogsugnar.
NO892984D0 (no) Polyeter-smoeremidler.
DE69016905T2 (de) Katheter.
DE69003042D1 (de) Katheter.
DE68901887D1 (de) Gewebedilatatoren.
FR2651681B1 (fr) Catheter.
DE68913568T2 (de) Multiplexer.
DE3865417D1 (de) Vinylester-latizes.
DE68924945T2 (de) Pufferspeicheranordnung.
DE68913744D1 (de) Dreidimensionales gestell.
FI910897A (fi) Foerbaettringar roerande (s)-norfluoxetin.
FI912361A0 (fi) Kablingsmaskin foer s/z-kabling.
FI923138A (fi) Tryckmedium-stoedanordning.
DE363229T1 (de) Sphygmomanometer.
ATE102481T1 (de) In vivo cytoprotektiv wirkende neurotrope alkohole.
IT1229015B (it) Tomografia.
NO894431L (no) Sidestykke for doerkarm.
ES2019679B3 (es) Mejoras en burletes.
IT8845507A0 (it) Pallone s.o.s. pirello
ATE102676T1 (de) Dreidimensionales gestell.
FI895480A0 (fi) Styv takkonstruktion.
ES1006103Y (es) Sujetadores femeninos con hombreras incorporadas.
ATE111362T1 (de) Markkatheter.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee